GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Burning Rock Biotech Ltd (LSE:BNR) » Definitions » 6-1 Month Momentum %

Burning Rock Biotech (LSE:BNR) 6-1 Month Momentum % : -21.22% (As of Sep. 26, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Burning Rock Biotech 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-09-26), Burning Rock Biotech's 6-1 Month Momentum % is -21.22%.

The industry rank for Burning Rock Biotech's 6-1 Month Momentum % or its related term are showing as below:

LSE:BNR's 6-1 Month Momentum % is ranked worse than
64.76% of 227 companies
in the Medical Diagnostics & Research industry
Industry Median: -2.82 vs LSE:BNR: -21.22

Competitive Comparison of Burning Rock Biotech's 6-1 Month Momentum %

For the Diagnostics & Research subindustry, Burning Rock Biotech's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Burning Rock Biotech's 6-1 Month Momentum % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Burning Rock Biotech's 6-1 Month Momentum % falls into.



Burning Rock Biotech  (LSE:BNR) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Burning Rock Biotech  (LSE:BNR) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Burning Rock Biotech 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Burning Rock Biotech's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Burning Rock Biotech Business Description

Traded in Other Exchanges
Address
No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, CHN, 510005
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.